share_log

Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(9.9%),3i Management LLC(9.9%), etc.

Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(9.9%),3i Management LLC(9.9%), etc.

Transcode Therapeutics | SC 13G:超過5%持股股東披露文件-3i, LP(9.9%),3i Management LLC(9.9%)等
美股SEC公告 ·  07/26 16:09
Moomoo AI 已提取核心訊息
On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
於2024年7月23日,由3i、LP、3i Management LLC和Maier Joshua Tarlow(統稱爲報告人)向美國證券交易委員會(SEC)提交了13G表格,表明他們持有TransCode Therapeutics公司的大量股權。該申報顯示,報告人合計持有TransCode Therapeutics普通股171萬6600股,佔截至2024年7月24日公司已發行普通股的9.9%。這些股份提供共同投票和支配權,由3i Management LLC管理,Maier Joshua Tarlow有權投票和處理這些股份。所有報告人的主要業務地址均在紐約市。此申報聲明股份的收購併非旨在改變或影響發行者的控制權,並且所有方已簽署聯合申報協議共同提交此申報和任何後續修正。
於2024年7月23日,由3i、LP、3i Management LLC和Maier Joshua Tarlow(統稱爲報告人)向美國證券交易委員會(SEC)提交了13G表格,表明他們持有TransCode Therapeutics公司的大量股權。該申報顯示,報告人合計持有TransCode Therapeutics普通股171萬6600股,佔截至2024年7月24日公司已發行普通股的9.9%。這些股份提供共同投票和支配權,由3i Management LLC管理,Maier Joshua Tarlow有權投票和處理這些股份。所有報告人的主要業務地址均在紐約市。此申報聲明股份的收購併非旨在改變或影響發行者的控制權,並且所有方已簽署聯合申報協議共同提交此申報和任何後續修正。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息